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CsA and FK506 up-regulate eNOS expression: Role of reactive
oxygen species and AP-1. Cyclosporine A (CsA) and FK506
increase endothelial nitric oxide synthase (eNOS) mRNA expres-
sion in cultured bovine aortic endothelial cells (BAEC). CsA
appears to increase eNOS mRNA levels mainly by increasing the
rate of transcription, although a small contribution of mRNA
stabilization could not be ruled out. CsA and FK506 induced an
increase of ROS synthesis with the fluorescent probe used,
DHR123. The ROS generating system glucose oxidase (GO)
increased the expression of eNOS mRNA in BAEC. This up-
regulation of eNOS mRNA by CsA or GO was abrogated by
catalase. As AP-1 is a redox-sensitive transcription factor and the
bovine eNOS promoter has an AP-1 consensus sequence, a role of
this factor in the up-regulation of eNOS mRNA was studied.
Electrophoretic mobility shift assays were consistent with an
increase in AP-1 DNA-binding activity in BAEC treated with CsA
or glucose oxidase. The potential participation of ROS and the
transcription factor AP-1 in the regulation of eNOS gene expres-
sion is suggested.
Since their introduction as immunosuppressors, CsA and
FK506 have been claimed to be very effective drugs,
especially in the field of transplantation. One of the most
well known side effects is damage to the vascular endothe-
lium [1, 2], which is in some cases associated with the
presence of hypertension and/or microangiopathic hemo-
lytic anemia. Although hypertension seems to be related to
perturbations in the balance of vasoconstrictors/vasodila-
tors within the vessel wall [3–6], little is known about the
molecular changes in signal transduction and gene expres-
sion induced by CsA or FK506 within the endothelium.
In lymphocytes, CsA and FK506 inhibit T-cell activation
by blocking the critical step between the formation of the
antigen-T cell receptor complex and subsequent gene ex-
pression. CsA and FK506 interact with a ubiquitously
distributed family of proteins named cyclophilins, the final
target of the immunosuppressant-cyclophilin complex be-
ing calcineurin, a serine-threonine specific protein phos-
phatase [7]. Calcineurin is activated after an increase in
intracellular calcium and acts by dephosphorylating the
cytoplasmic subunit of a transcription factor, nuclear factor
of activated T-cells (NF-AT), which is crucial in promoting
transcription of T-cell genes participating in the immune
response [8]. Thus, CsA is immunosuppressive by inhibiting
calcineurin-dependent NF-AT dephosphorylation.
However, little is known about the pathways involved in
other effects of these drugs, mainly those implied in the
development of cell toxicity. In this sense, it has been
proposed that reactive oxygen species (ROS) could be one
of the mediators involved in the toxic actions of CsA [9–11]
and, hence, the treatment with antioxidants improves acute
CsA nephrotoxicity [12]. On the other hand, ROS have
been proposed as biological mediators of cell signals [13].
Thus, Sundaresan and colleagues demonstrated that
PDGF-induced cell proliferation was dependent on the
synthesis of H2O2 [14], and the ability of these ROS to
activate some transcription factors, such as NF-kB or AP-1,
has been clearly demonstrated [15–17]. In this work we
analyze the ability of immunosuppresors to augment the
synthesis of ROS and link this effect to the previously
described up-regulation of eNOS by CsA [18], possibly




CsA was a generous gift from Sandoz Pharmaceuticals.
FK506 was a generous gift from Fujisawa. Salmon sperm
DNA, phenylmethylsulfonyl fluoride (PMSF), formalde-
hyde, glucose oxidase, catalase, leupeptin, antipain, trypsin
inhibitor, pepstatin, dithiothreitol (DTT), and dichlorben-
zimidazolriboside (DBR) were purchased from Sigma
Chemical (St. Louis, MO, USA). Guanidinium thiocyanate,
formamide, Nonidet P-40 were from Fluka (St. Louis, MO,
USA). The fluorescent probe dihydrorhodamine 123
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(DHR123) was purchased from Molecular Probes (Eu-
gene, OR, USA). RPMI 1640 medium, bovine calf serum,
trypsin-EDTA (0.02%) and penicillin-streptomycin were
purchased from Bio-Whittaker (Walkersville, MD, USA).
The nylon filters, deoxy-[32P]-cytidine triphosphate and
DNA labeling kit (Rediprime) were purchased from Am-
ersham (Buckinghamshire, UK). X-OMAT films were from
Kodak (Rochester, NY, USA).
Cell culture
BAEC were isolated using previously described methods
[19].
Measurement of ROS synthesis
ROS synthesis in BAEC was measured by flow cytom-
etry, by using modifications of techniques previously de-
scribed [20]. Briefly, endothelial cells (2 3 106 cells in
RPMI) loaded with 2 mM DHR123 were treated with CsA,
FK506 or vehicle (0.01% ethanol). Upon the cellular
synthesis of ROS, the intracellular DHR123 is irreversibly
converted to the green fluorescent compound rhodamine
123 (R123). R123 is membrane-impermeable and accumu-
lated in the cells. Flow cytometry analysis was carried out
with an EPICS XL cytometer (Coulter Corp., Hileah, FL,
USA) equipped with a ion argon laser, using an excitation
wavelength of 488 nm. Fluorescence emission signals were
collected with a 525 nm band pass filter. On each sample,
specific fluorescence from 10,000 cells was estimated, after
selection on gated population of biparametric FS, SS dot
plot. Fluorescence signals were collected using logarithmic
amplifiers.
RNA isolation and Northern analysis
Total cellular RNA was isolated by the guanidinium lysis
method, as described [21]. For Northern analysis, 10 mg/
lane of total RNA were subjected to electrophoresis in 1%
agarose gels containing 0.66 M formaldehyde and trans-
ferred to nylon filters, as described [22]. Membranes were
hybridized with a [32P]-labeled bovine eNOS cDNA [23],
and washed at final stringency conditions of 0.2 3 SSC,
0.1% SDS at 42°C for 30 minutes, and then finally exposed
to X-OMAT film for 24 hours. The densitometric analysis
of the films was performed with an Apple scanner and
appropriate software.
Preparation of nuclear extracts and electrophoretic
mobility shift assay (EMSA)
A modification of the method of Schreiber et al was used
[24]. At the end of each experimental period, BAEC were
washed twice with PBS, scraped and transferred to micro-
centrifuge tubes. Cell pellets were resuspended in 400 ml of
Buffer B (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM
EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF and 1
mg/ml of leupeptin, antipain, trypsin inhibitor and pepstatin
A). After 15 minutes at 4°C, 25 ml of 10% Nonidet P-40 was
added. Tubes were vigorously vortexed for 10 seconds and
nuclei were sedimented for 30 seconds at 23,000 g. Nuclear
pellets were resuspended in 50 ml of Buffer C (20 mM
HEPES pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA,
1 mM DTT, 1 mM PMSF and protease inhibitors at 1 mg/ml)
and vigorously rocked at 4°C for 15 minutes. They were
then centrifuged for five minutes, 23,000 g at 4°C and the
supernatants aliquoted at 280°C. Before use their protein
content was determined by the BIO-RAD protein assay
(Laboratories GmbH, Munich, Germany). Oligonucleo-
tides were synthesized in a Beckman Oligo 100 M DNA
synthesizer. The oligonucleotide sequence corresponding
to the AP-1 site in the bovine eNOS promoter was:
59 GGC CCC CAA CTT GAG TCA CAG GGG GTG 39
39 GGG GGT TGA ACT CAG TGT CCC CCA CGG 59
Primers were annealed by incubation for five minutes at
85°C in Buffer D (50 mM Tris-HCl pH 7.5, 1 mM spermi-
dine, 10 mM MgCl2 and 5 mM DTT), and slowly cooled
down to room temperature. Two hundred nanograms of
these primers were end-labeled using Klenow DNA poly-
merase (Pharmacia, USA) in the presence of 20 mCi of
[32P]-dCTP. For binding reactions, approximately 6,000
cpm of the end-labeled oligonucleotide probes were incu-
bated with 7 mg of nuclear extract and 1 mg of poly (dI-dC)
in binding buffer (10 mM Tris-HCl, pH 7.9, 50 mM NaCl,
4% glycerol, 1 mM DTT) at 4°C for 30 minutes. Protein-
DNA complexes were separated by electrophoresis, in a
6% non-denaturing polyacrylamide gel in 0.25 3 TBE
buffer at 20 mA˚, and visualized by autoradiography. For
competition experiments 125-fold molar excess of compet-
itor DNA was coincubated with the labeled oligonucleotide
probe.
Fig. 1. Effect of immunosuppressors cyclosporine A (CsA) and FK506 on
endothelial nitric oxide synthase (eNOS) expression in cultured bovine
aortic endothelial cells. Cells were incubated with 1 mM CsA or 1 mM
FK506. A representative Northern blot experiment of hybridization with
eNOS is shown. The blot shown is representative of three.
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RESULTS
Both calcineurin-inhibiting immunosuppressors CsA and
FK506 up-regulate eNOS mRNA in BAEC. This up-
regulation was higher with 1 mM FK506 than with 1 mM CsA
(Fig. 1).
To find out if this up-regulation could be related to an
increase in the transcription rate and/or stabilization of the
transcript, experiments of inhibition of RNA synthesis were
designed. Ten micromolar of dichlorbenzimidazolriboside
(DBR) was used to inhibit RNA polymerase II. Since
preincubation with DBR nearly abolished the up-regula-
tion of eNOS mRNA by CsA (Fig. 2), an increase in the
transcriptional rate could be inferred. A small contribution
of mRNA stabilization could not be ruled out.
Figure 3 shows the effect of CsA or FK506 on ROS
synthesis in cultured BAEC. In these experiments, cells
were incubated with CsA or FK506 for 70 minutes, and
ROS accumulation was measured as oxidation of the
DHR123 added for the last 60 minutes. CsA and FK506
induced a significant increment in rhodamine-dependent
fluorescence at concentrations of 1 mM.
When glucose oxidase (a ROS-generating enzyme) was
added to the glucose-containing incubation media, an
increase in the mRNA expression of eNOS was achieved.
The up-regulation of eNOS mRNA by CsA or glucose
oxidase was abolished when catalase was present in the
incubation media (Fig. 4).
In an effort to investigate potential mechanisms respon-
sible for the effects of ROS, and therefore of CsA and
FK506 on the expression of eNOS, the possible role of
AP-1 was explored, as this transcription factor may poten-
tially interact with an AP-1 cis-regulatory sequence in the
bovine eNOS promoter. As shown in Figure 5 both CsA
and glucose oxidase augmented AP-1 binding to the AP-1
oligonucleotide containing the cis-regulatory sequence of
the eNOS promoter as determined by EMSA. In the case of
glucose oxidase the maximum binding occurred at 30
minutes, in contrast to the effect of CsA, which had a peak
around one to four hours.
DISCUSSION
The present results show that two immunosuppressors,
CsA and FK506, up-regulate eNOS mRNA. As the inhibi-
tion of the phosphatase activity of calcineurin is the target
of both drugs, a possible implication of a calcineurin-
mediated signal transduction pathway should be ruled out
in future experiments. Since DBR-dependent inhibition of
Fig. 2. Effects of a RNA polymerase II inhibitor on the CsA up-regulated expression of eNOS. Where indicated bovine aortic endothelial cells were
preincubated 30 minutes with 10 mM dichlorbenzimidazolriboside (DBR), without removing it from the incubation media during the whole experimental
period with CsA or vehicle (12 hr). A representative Northern blot experiment of hybridization with eNOS is shown. The blot shown is representative
of three.
Fig. 3. Synthesis of reactive oxygen species (ROS) in cultured aortic
endothelial cells exposed to CsA or FK506. Cells were incubated with 1 mM
CsA or 1 mM FK506, at 37°C, and the ROS production was evaluated with
a ROS-sensitive fluorescent probe, dihydrorhodamine (DHR123). Results
shown are the mean 6 SEM of three different experiments. The symbol (*)
indicates P , 0.05 versus control.
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the synthesis of new mRNA nearly abolished the up-
regulation of eNOS mRNA by CsA, an increased transcrip-
tional rate appears to explain this phenomenon, although a
small component of mRNA stabilization could not be
excluded. Both CsA and FK506 increased ROS accumula-
tion in BAEC. Glucose oxidase, a ROS-generating system,
mimicked the up-regulation of eNOS by CsA and catalase
inhibited the action of CsA or GO on the expression of
eNOS mRNA. These data support a role for ROS in this
up-regulation, and suggest the participation of a redox-
sensitive transcriptional factor. AP-1 is a redox-sensitive
transcription factor and an AP-1-responsive cis-regulatory
sequence exists in the 59 regulatory region of the bovine
eNOS gene. Our data are consistent with an increase in the
binding of the transcription factor AP-1 to its cis-regulatory
element in the eNOS promoter after treatment with CsA or
glucose oxidase, suggesting its participation in the up-
regulation of eNOS by immunosupressors. Of interest, CsA
has been reported to enhance calcium-dependent activa-
tion of AP-1 in a lymphoma cell line [25] and is also capable
of increasing the DNA-binding activity of AP-1 [26].
In conclusion, the present experiments support a role for
ROS as mediators of the CsA-induced eNOS up-regula-
tion, and suggest the participation of the redox-sensitive
transcription factor AP-1. Because of this ability to up-
regulate eNOS mRNA expression, a relevant role for ROS
in the hemodynamic changes associated with pathophysio-
logical situations in which these metabolites are increased
could also be proposed.
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